share_log

石藥集團：自願公告 - 高選擇性MAT2A抑制劑(SYH2039)獲美國臨床試驗批准

CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Hong Kong Stock Exchange ·  Apr 26 04:31
Summary by Moomoo AI
石藥集團有限公司宣佈，其開發的化藥1類新藥，高選擇性MAT2A抑制劑SYH2039，已獲得美國食品藥品監督管理局(FDA)批准進行臨床試驗。此藥物專門針對MTAP缺失型腫瘤細胞，並已於2024年3月獲准在中國開展臨床試驗。SYH2039具有優異的體內外活性和安全性，有望成為領先的抗腫瘤藥物。石藥集團表示，該產品對於缺乏有效治療的MTAP缺失腫瘤具有重大的臨床開發價值。公告由董事會主席蔡東晨於2024年4月26日發出。
石藥集團有限公司宣佈，其開發的化藥1類新藥，高選擇性MAT2A抑制劑SYH2039，已獲得美國食品藥品監督管理局(FDA)批准進行臨床試驗。此藥物專門針對MTAP缺失型腫瘤細胞，並已於2024年3月獲准在中國開展臨床試驗。SYH2039具有優異的體內外活性和安全性，有望成為領先的抗腫瘤藥物。石藥集團表示，該產品對於缺乏有效治療的MTAP缺失腫瘤具有重大的臨床開發價值。公告由董事會主席蔡東晨於2024年4月26日發出。
PETROLEUM GROUP CO., LTD. ANNOUNCED THAT ITS DEVELOPED NEW CHEMICAL CLASS 1 DRUG, THE HIGHLY SELECTIVE MAT2A INHIBITOR SYH2039, HAS BEEN APPROVED FOR CLINICAL TRIALS BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). The drug is specialized for MTAP-deficient tumor cells and was approved for clinical trials in China in March 2024. SYH2039 has excellent in vitro activity and safety, and is expected to become a leading anti-tumor drug. The pharmaceutical group said the product has significant clinical development value for MTAP-deficient tumors for the lack of effective treatment. The announcement was made by Chairman of the Board of Directors Tung Chen on 26 April 2024.
PETROLEUM GROUP CO., LTD. ANNOUNCED THAT ITS DEVELOPED NEW CHEMICAL CLASS 1 DRUG, THE HIGHLY SELECTIVE MAT2A INHIBITOR SYH2039, HAS BEEN APPROVED FOR CLINICAL TRIALS BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). The drug is specialized for MTAP-deficient tumor cells and was approved for clinical trials in China in March 2024. SYH2039 has excellent in vitro activity and safety, and is expected to become a leading anti-tumor drug. The pharmaceutical group said the product has significant clinical development value for MTAP-deficient tumors for the lack of effective treatment. The announcement was made by Chairman of the Board of Directors Tung Chen on 26 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more